Eteplirsen Patent Expiration
Eteplirsen is Used for treating Duchenne Muscular Dystrophy by increasing the production of functional dystrophin protein in patients with a specific gene mutation amenable to exon 51 skipping. It was first introduced by Sarepta Therapeutics Inc
Eteplirsen Patents
Given below is the list of patents protecting Eteplirsen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Exondys 51 | US10337003 | Compositions for treating muscular dystrophy | Mar 14, 2034 | Sarepta Theraps Inc |
| Exondys 51 | US10364431 | Compositions for treating muscular dystrophy | Mar 14, 2034 | Sarepta Theraps Inc |
| Exondys 51 | US9506058 | Compositions for treating muscular dystrophy | Mar 14, 2034 | Sarepta Theraps Inc |
| Exondys 51 | USRE47769 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Feb 02, 2029 | Sarepta Theraps Inc |
| Exondys 51 | US9243245 | Means and methods for counteracting muscle disorders | Oct 27, 2028 | Sarepta Theraps Inc |
| Exondys 51 | USRE48468 | Means and methods for counteracting muscle disorders | Oct 27, 2028 | Sarepta Theraps Inc |
| Exondys 51 | US10781451 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Exondys 51 | US8486907 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Exondys 51 | US9018368 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Exondys 51 | USRE47751 | Antisense oligonucleotides for inducing exon skipping and methods of use thereof | Jun 28, 2025 | Sarepta Theraps Inc |
| Exondys 51 | US10533174 | Splice-region antisense composition and method |
May 04, 2021
(Expired) | Sarepta Theraps Inc |
| Exondys 51 | US9416361 | Splice-region antisense composition and method |
May 04, 2021
(Expired) | Sarepta Theraps Inc |
Eteplirsen's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List